Fuji Pharma Co Ltd 2025 IR
The report outlines Fuji Pharma Co., Ltd.'s business activities, medium- to long-term strategies, and ESG initiatives for the fiscal year ended September 30, 2024. Key highlights include the launch of the Long-term Vision for 2035 and the new Mid-Term Business Plan (2025-2029), which focus on expanding the company's core women's healthcare, biosimilars, and global CMO businesses. The company introduced Alyssa® combination tablets, a new dysmenorrhea treatment, and expanded its biosimilar pipeline in partnership with Alvotech. On the environmental front, Fuji Pharma committed to reducing Scope 1 and 2 emissions by 42% by 2030, receiving SBTi approval, and signed an offsite solar PPA to transition its Toyama Plant to renewable energy.
Company: Fuji Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2025
Type: IR
Pages: 27
Fuji Pharma Co Ltd
Corporate Report
The report outlines Fuji Pharma Co., Ltd.'s business activities, medium- to long-term strategies, and ESG initiatives for the fiscal year ended September 30, 2024. Key highlights include the launch of the Long-term Vision for 2035 and the new Mid-Term Business Plan (2025-2029), which focus on expanding the company's core women's healthcare, biosimilars, and global CMO businesses. The company introduced Alyssa® combination tablets, a new dysmenorrhea treatment, and expanded its biosimilar pipeline in partnership with Alvotech. On the environmental front, Fuji Pharma committed to reducing Scope 1 and 2 emissions by 42% by 2030, receiving SBTi approval, and signed an offsite solar PPA to transition its Toyama Plant to renewable energy.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Oct 1, 2023 - Sep 30, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Women in Management
Employees